ARIX.L

Arix Bioscience Plc
Director/PDMR Shareholding
6th February 2023, 17:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.

Arix Bioscience PLC (ARIX)
Director/PDMR Shareholding

06-Feb-2023 / 17:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Arix Bioscience plc
("Company")

PDMR notification & Director Shareholding

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The Company has been notified that Peregrine Moncreiffe, Director and Chairman of the Company purchased 200,000 Ordinary shares of 0.001 pence each in the Company (“Shares”) on 06 February 2023 at a price of 108.5 pence per share.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Peregrine Moncreiffe

2

 

Reason for the notification

 

a)

 

Position/status

 

 Non-Executive Director and Chair of the Board

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Share purchase
  1.  

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

 

£1.085

200,000

 

 

d)

 

Aggregated information

 

- Aggregated volume

200,000

- Price

£217,000.00

e)

 

Date of the transaction

 

06 February 2023

 

f)

 

Place of the transaction

 

Outside a trading venue

For further information please contact:
Kin Company Secretarial Limited, Company Secretary
+44 20 8819 6486
ISIN: GB00BD045071
Category Code: DSH
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 221131
EQS News ID: 1552927

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1552927&application_name=news&site_id=acquiremedia3]]>
TwitterFacebookLinkedIn